The Logistics of CAR-T in Hematologic Malignancies

By Chadi Nabhan, MD, MBA, FACP - Last Updated: August 1, 2023

Navneet Majhail, MD, MS, Physician-in-Chief of Blood Cancers at the Sarah Cannon Cancer Institute, delves into the intricacies of chimeric antigen receptor (CAR) T-cellular therapy, discussing the logistics and challenges involved with these therapies.

Dr. Majhail explores strategies to improve access to CAR-T therapy and discusses the role of CAR-T amidst the availability of bispecific antibodies as treatments for blood cancers.

Find all episodes of The HemOnc Pulse here.

What are the Controversies Surrounding MRD in Blood Cancers?

HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD

Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Aaron Goodman, MD, Tells Us the 'Crux' of Castleman Disease

Is MRD Negativity the New Benchmark in ALL Treatment Strategies?

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

The Logistics of CAR-T in Hematologic Malignancies

Related